The research team, led by investigators at the First Affiliated Hospital of Xinjiang Medical University, combined single-cell RNA sequencing, spatial transcriptomics, CRISPR-based gene editing, pharmacological pathway modulation, and xenograft modeling to trace SOX9’s role across both time and tissue space. Using a publicly available single-cell dataset, they reconstructed a pseudotime trajectory with Monocle3, mapping the continuous transition from astrocytes to malignant glioma cells. The analysis revealed substantial cellular heterogeneity within glioma samples, encompassing malignant cells alongside astrocytes, macrophages, T cells, B cells, monocytes, neurons, fibroblasts, and endothelial cells.

The most consequential finding to emerge from the trajectory analysis was SOX9’s temporal behavior. Its expression was concentrated almost exclusively in astrocyte and malignant cell populations, and along the inferred developmental arc it peaked early and then declined steadily as cells matured into malignant states. Correlation analysis confirmed this downward trend, with Pearson and Spearman coefficients both strongly negative and highly significant. At the level of trajectory nodes, SOX9 dominated the early, astrocyte-rich segments and faded in the terminal malignant zones, a pattern inconsistent with the conventional view of SOX9 as a constitutively active stemness factor.

To probe what SOX9 might be doing during that early window, the researchers scored the activity of the Hippo pathway, a master regulator of organ size and stem cell fate whose downstream effectors YAP and TAZ are established drivers of glioblastoma plasticity. Using Gene Set Variation Analysis, they quantified an upstream kinase module, including MST1/2, LATS1/2, SAV1, MOB1A/B, NF2, and WWC1, and a canonical YAP/TAZ target module containing genes such as CTGF, CYR61, ANKRD1, AXL, and BIRC5. Both modules showed inverse relationships with SOX9 expression, and generalized additive modeling revealed that pseudotime and SOX9 each contributed independent, nonlinear effects on pathway activity. In other words, the SOX9–Hippo relationship was phase-dependent, strongest during early-to-intermediate stages of the transition and not a simple monotonic association.

Spatial transcriptomics added a second, geographic dimension to the story. Analyzing four anatomically distinct regions of glioblastoma tissue—the tumor–normal interface, the pure tumor core, the perivascular compartment, and the tumor–necrosis interface—the team mapped SOX9 expression against the probability that each spatial spot contained malignant cells. The coupling between SOX9 and malignancy was weak or unstable at the tumor edges and the necrotic margin, modest in the tumor core, and most robust in the perivascular niche. There, SOX9 expression was markedly elevated, correlations with malignant cell probability were strongest, and neighborhood enrichment and spatial autocorrelation statistics all confirmed significant co-localization.

This regional specificity is biologically meaningful. The perivascular niche has long been recognized as a reservoir for stem-like glioblastoma cells, bathed in vascular, hypoxic, and paracrine signals that nurture cellular plasticity. The findings suggest that SOX9-dependent reprogramming is not only time-restricted but niche-conditioned, with perivascular regions providing the most permissive anatomical context for effective SOX9–Hippo–YAP/TAZ coupling. Elsewhere in the tumor, downstream malignant programs may be sustained through alternative inputs, weakening the spatial coherence of the axis.

Functional experiments brought the correlation studies into the laboratory. Using lentiviral vectors, the team generated U87 glioma cells stably overexpressing SOX9 and used CRISPR/Cas9 to knock out the gene in U251 cells, validating the edits by Sanger sequencing and confirming a frameshift-inducing deletion in the knockout clone. SOX9 overexpression modestly increased proliferation, migration, and invasion while reducing apoptosis, whereas SOX9 knockout produced the opposite phenotype across wound-healing, Transwell invasion, and flow-cytometric apoptosis assays. Critically, treatment with XMU-MP-1, an inhibitor of the upstream Hippo kinases MST1/2, partially rescued the defects caused by SOX9 loss, linking SOX9 function experimentally to Hippo pathway state.

Phosphorylation-level Western blotting sharpened the mechanistic picture. SOX9 overexpression raised the ratio of phosphorylated to total YAP and lowered the phosphorylated-to-total MOB1 ratio, while SOX9 knockout produced the reciprocal pattern. XMU-MP-1 shifted both readouts toward the SOX9-overexpression signature, and total MOB1 remained unchanged across groups, indicating that the pathway rewiring was phosphorylation-dependent rather than a simple change in protein abundance. YAP and TAZ mRNA and protein levels rose with SOX9 gain and fell with SOX9 loss, and drug treatment partially restored them in SOX9-deficient cells, extending the transcriptomic associations to protein-level pathway readouts.

In vivo, the story held. Subcutaneous xenografts in nude mice showed that SOX9 overexpression significantly accelerated U87-derived tumor growth from day 14 onward, while SOX9 knockout markedly suppressed U251-derived tumors. XMU-MP-1 treatment further enlarged SOX9-overexpressing tumors and partially reversed the growth inhibition caused by SOX9 loss. Histopathology mirrored these dynamics: SOX9-overexpressing tumors displayed increased necrosis and nuclear atypia, whereas knockout tumors showed milder pathology, and the drug partially reversed both patterns. Ki67 immunohistochemistry confirmed the corresponding changes in proliferative activity, and CD68 staining revealed that myeloid and macrophage-like cell accumulation also shifted with SOX9 status, adding an immune dimension to the tumor microenvironmental effects.

Taken together, the study proposes what the authors call an early priming–late decoupling model. SOX9 acts early, at the moment of astrocyte-to-malignant conversion, to initiate Hippo–YAP/TAZ-linked malignant reprogramming. Once downstream transcriptional networks consolidate, the tumor becomes progressively less dependent on sustained SOX9 expression, which explains why stemness programs can persist in advanced disease even as SOX9 levels fall. The translational implication is pointed: therapies aimed at SOX9 may work best before malignant programs fully consolidate, whereas in later-stage tumors, blocking SOX9 alone may prove insufficient. The results argue for stage-specific and niche-aware strategies targeting the SOX9/Hippo/YAP–TAZ axis, particularly in the perivascular compartment where the axis is most strongly engaged. Limitations remain, including the reliance on public cohorts of limited size, established cell lines, and subcutaneous rather than orthotopic models, and the absence of YAP/TAZ nuclear localization data or a second pathway inhibitor. Even so, the study repositions SOX9 from a static stemness marker to a dynamic state-switch regulator, and it provides a conceptual framework for timing future interventions against one of medicine’s most stubborn cancers.

Subject of Research: The temporal role of SOX9 in priming Hippo–YAP/TAZ signaling during glioblastoma stemness acquisition

Article Title: Early SOX9 Activation Primes Hippo–YAP/TAZ Rewiring During Glioblastoma Stemness Acquisition

Article References: Early SOX9 Activation Primes Hippo–YAP/TAZ Rewiring During Glioblastoma Stemness Acquisition. (n.d.). https://doi.org/10.1111/jcmm.71341

Image Credits: AI Generated

DOI: 10.1111/jcmm.71341

Keywords: glioblastoma, SOX9, Hippo pathway, YAP/TAZ, glioma stem cells, pseudotime analysis, spatial transcriptomics, perivascular niche, XMU-MP-1, CRISPR, tumor plasticity, xenograft

Ion channels embedded in tumor cell membranes present a unique “fingerprint” that governs cellular signaling pathways fundamental to malignancy. These tumor-specific ion channel profiles interact intricately with pathways controlling proliferation, differentiation, and migration, markedly influencing disease trajectory and patient outcomes. For instance, the transient receptor potential vanilloid 1 (TRPV1) channel displays a dualistic role across tumor types. In multiple myeloma, TRPV1 inhibition intensifies endoplasmic reticulum stress and mitochondrial calcium overload, thereby synergizing with proteasome inhibitors like bortezomib to surmount drug resistance. Conversely, gastric cancer cells with diminished TRPV1 expression experience reduced calcium/calmodulin-dependent kinase β (CaMKKβ)/AMP-activated protein kinase (AMPK) activity, lifting repression on cyclin D1 and matrix metallopeptidase 2 (MMP2) and promoting invasive phenotypes linked to poor prognosis.

The interplay between ion channels and tumor microenvironmental cues further accentuates tumor aggressiveness and immune evasion. In medulloblastoma, the inward rectifier potassium channel Kir2.1 engages with ADAM10 independent of its ion-conducting role, facilitating Notch2 receptor cleavage and subsequent activation of oncogenic circuits such as the C-Myc/Slug axis. This molecular cascade advances epithelial-to-mesenchymal transition (EMT), invasion, and correlates with diminished 5-year survival rates. Additionally, the tumor milieu’s elevated extracellular potassium concentration acts through Kir2.1 to reprogram tumor-associated macrophages (TAMs), suppressing pro-inflammatory gene expression while heightening immunosuppressive mediator secretion. Glioblastoma exemplifies another dimension, where the EAG2 potassium channel and Kvβ2 subunit complex localizes at the tumor-brain interface, modulating calcium transients that underpin enhanced proliferation, invasive capacity, and resistance to chemotherapeutic agents.

Capitalizing on the crystalline structures and functional dynamics of ion channel complexes, rational drug design has yielded promising therapeutic candidates. The compound K90-114TAT, engineered based on the crystal structure of Kvβ2, disrupts EAG2-Kvβ2 interactions, resulting in significant tumor burden reduction in glioma preclinical models, including those resistant to standard therapy with temozolomide. Further exploitation of tumor bioenergetics and electrophysiology is embodied by compounds such as the K⁺/H⁺ transporter known as Compound 2, which selectively targets mitochondrial pH gradients and hyperpolarization in CSCs. This targeted disruption provokes reactive oxygen species (ROS) surges capable of eradicating ovarian CSCs expressing the CD133 marker, marking a pivotal advance in combating tumor relapse and chemoresistance.

Electrical therapies have surged to the forefront of adjunctive cancer treatment modalities by exploiting intrinsic tumor electrophysiology. Tumor treating fields (TTFields), composed of low-intensity alternating electric fields, perturb mitotic spindle dynamics by interfering with tubulin and septin polymerization, leading to mitotic arrest and tumor cell death. Concurrently, TTFields enhance membrane permeability and transiently disrupt the blood-brain barrier, thereby augmenting the delivery and efficacy of chemotherapeutic agents such as temozolomide. Clinical data underscore that the integration of TTFields with chemotherapy confers extended survival benefits in glioblastoma patients, a notoriously refractory cancer.

Multimodal therapeutic strategies leverage the synergy between electrophysiologically targeted agents and immunomodulatory treatments to surmount barriers imposed by the immunosuppressive tumor microenvironment. For example, Kir2.1 inhibitors paired with programmed death-1 (PD-1) checkpoint inhibitors have demonstrated efficacy in reversing TAM polarization from the tumor-promoting M2 phenotype to a more cytotoxic M1 state. Similarly, irreversible electroporation (IRE) combined with Toll-like receptor 3 and 9 (TLR3/9) agonists and PD-1 blockade potentiates CD8⁺ T cell-mediated cytotoxicity, thereby orchestrating robust antitumor immune responses.

Clinical translation of these electrophysiological therapies has shown marked promise across diverse malignancies. A comprehensive pan-European clinical study examining electrochemotherapy (ECT) for cutaneous cancers reported remarkably high objective response rates, with vascular tumors such as Kaposi’s sarcoma and basal cell carcinoma exhibiting the greatest sensitivity. High-frequency irreversible electroporation (H-FIRE), a refinement of IRE technology, has been effectively applied to localized prostate cancer, achieving precise tumor ablation while sparing surrounding tissues and maintaining genitourinary function, with minimal adverse effects. Nanotechnology-driven delivery systems further augment therapeutic specificity and potency. The M-UCN-T nanoparticle, for instance, releases nitric oxide in response to near-infrared light stimulation and intracellular glutathione, simultaneously activating endoplasmic reticulum-localized TRPV1 channels to trigger calcium-induced immunogenic cell death, demonstrating profound glioma suppression absent systemic toxicity.

Despite these advances, translational challenges remain formidable. Combining IRE with γδ T-cell adoptive therapies extends survival in preclinical models but poses risks such as gastrointestinal bleeding and biliary obstruction, limiting its applicability in patients with compromised organ function. Similarly, H-FIRE requires more extensive clinical trials to validate long-term efficacy and assess its utility across various tumor types. Addressing these limitations, ongoing research focuses on engineering pH-responsive delivery vectors for TRPV1 modulators, optimized to target the bone marrow niche and alleviate cancer-associated neuropathic pain. Concurrently, the development of dynamic immune monitoring platforms aims to provide real-time insights into treatment responses and immune cell dynamics.

Looking forward, the integration of advanced nanocarriers, molecularly tailored ion channel inhibitors, and precision bioelectrical therapies heralds a new era in cancer treatment. Innovations such as the M-UCN-T system, which achieves over 90% tumor suppression in preclinical models, exemplify the potential impact on refractory malignancies. Collectively, these multidisciplinary efforts underscore the importance of tumor electrophysiology not only as a fundamental facet of cancer biology but also as a strategic axis for therapeutic innovation, with prospects for improved survival and quality of life for patients across the oncological spectrum.

Subject of Research: Not applicable
Article Title: Not provided
Web References: http://dx.doi.org/10.1002/imm3.70002
References: Not provided
Image Credits: Kailai Li, Yasi Zhang, Yue Qian, Hu Qin, Hongtian Zhang, Chaoqun Li, Changmin Peng, Jian Zhang, Suyin Feng
Keywords: Cancer